Transfusion management in the era of magrolimab (<scp>Hu5F9‐G4</scp>), an anti‐<scp>CD47</scp> monoclonal antibody therapy
Nirupama Singh, Julie Staves, Jill R. Storry, Jason B. Dinoso, Camille Renard, Parul Doshi, Lisa D. Johnson, Connie M. Westhoff, Michael Murphy
Abstract
Nirupama Singh received a consultant fee from Gilead Sciences. Julie Staves received support for attending meetings from Immulab and is Chair of the Transfusion Laboratory Manager Subgroup of the UK National Blood Transfusion Committee. Jill R. Storry received support from the Swedish Research Council, received honorarium from Ortho Clinical Diagnostics, Grifols Diagnostic Solutions, and Wiley, is Vice President of the International Society of Blood Transfusion, is a chapter lead (Immunohematology; 21st Edition Blood Guide) for the Council of Europe European Directorate for the Quality of Medicines and HealthCare, and is an owner of BLUsang AB/receives royalties from a patent. Jason Dinoso is an employee of Gilead Sciences. Camille Renard is an employee of and owns stock in Gilead Sciences. Parul Doshi is an employee of Gilead Sciences. Lisa Johnson is an employee of and owns stock in Gilead Sciences. Connie Westhoff received a consultant fee from Gilead Sciences and is a participant on the Data and Safety Monitoring Board for the Cerus Pathogen Inactivation System. Michael F. Murphy received a consultant fee from Gilead Sciences and is a participant on the Haemonetics Scientific Advisory Council.